Publication

FLUORESCENCE IN SITU HYBRIDIZATION (FISH) ENHANCEMENT USING MICROFLUIDIC FLOW FOR AN ACCURATE, FAST AND ECONOMICAL ASSESSMENT OF HER2 STATUS IN BREAST CANCER

Martinus Adela Maria Gijs, Raphaël Etienne Jean Trouillon, Huu Tuan Nguyen
2016
Conference Papers

Abstract

The fluorescence in situ hybridization (FISH) is the gold standard in human epidermal growth factor receptor 2 (HER2) status assessment in breast cancer. The dissemination of the technique is impeded by the cost of reagents and long experimental time. For overcoming these limitations, we have developed a new method for implementing FISH for HER2 assessment for tissue analysis based on microfluidic technology.

Official source

https://infoscience.epfl.ch/entities/publication/3109e71e-89e4-476e-8e97-25ff11667bec

About this result

This page is automatically generated and may contain information that is not correct, complete, up-to-date, or relevant to your search query. The same applies to every other page on this website. Please make sure to verify the information with EPFL's official sources.

Graph Chat

Chat with Graph Search

Ask any question about EPFL courses, lectures, exercises, research, news, etc. or try the example questions below.

DISCLAIMER: The Graph Chatbot is not programmed to provide explicit or categorical answers to your questions. Rather, it transforms your questions into API requests that are distributed across the various IT services officially administered by EPFL. Its purpose is solely to collect and recommend relevant references to content that you can explore to help you answer your questions.

FLUORESCENCE IN SITU HYBRIDIZATION (FISH) ENHANCEMENT USING MICROFLUIDIC FLOW FOR AN ACCURATE, FAST AND ECONOMICAL ASSESSMENT OF HER2 STATUS IN BREAST CANCER

Chat with Graph Search

CircCDYL Association With hnRNPL Modulates CDYL Isoform Switching in Breast Cancer Cells

Improved microfluidic transcriptome based screening methods

Association between endocrine adjuvant therapy intake timing and disease-free survival in patients with high-risk early breast cancer: results of a sub-study of the UCBG- UNIRAD trial